CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with ...

Baby KJ's medical team intend to ask the FDA to start a clinical trial that would be open to patients with seven different ...

The idea that a single-celled bacterium can defend itself against viruses in a similar way as the 1.8-trillion-cell human immune system is still “mind-blowing” for molecular biologist Joshua Modell of ...

Gene editing, led by CRISPR, is expanding rapidly beyond medical applications, offering new opportunities across various biotech industries. Technological breakthroughs are fueling acceleration and ...

CRISPR Therapeutics’ stock is surging as in-vivo therapies show promise. Learn about CRSP stock's risks, long-term upside, ...

In May, a historic moment in science and medicine was captured in a single photo that circulated across news outlets ...

One of the most revolutionary tools in cutting-edge medicine is a molecular scalpel so precise that it can modify defective ...

The influenza A virus (IAV) has been the cause of six major flu pandemics, responsible for 50 to 100 million deaths globally.

CRISPR-based tools can’t easily access the DNA in these organelles, but researchers are finding other ways in.